Additional analyses of all events through the end of the intervention period and post-trial observational follow-up data showed reduction of MACE and all-cause death with SBP target <120 mmHg compared to SBP target <140 mmHg. With poll.
The Heart Failure Association of the European Society of Cardiology has published a consensus document with patient profiles that may be relevant for treatment implementation in HFrEF patients.
Following the results from the EMPEROR-Reduced trial, the CHMP has issued a recommendation for empagliflozin in patients with symptomatic chronic HFrEF with or without T2DM to reduce the combined risk of CV death or HF hospitalization.
The ERA-EDTA has launched the "Strong Kidneys" campaign to raise awareness about kidney disease and its prevention.
EAS 2021 This DA VINCI subanalysis showed that the proportion of patients achieving their risk-based LDL-c goal using the 2016 and 2019 ESC/EAS guidelines in patients on lipid lowering therapy for primary and secondary care was lower in Central- and East- Europe than in North- or West-Europe.
ACC 2021 In patients undergoing coronary angiography in the INSPIRE registry, higher levels of EPA unadjusted and adjusted for DHA were associated with lower MACE and in contrast, higher DHA levels adjusted for EPA were associated with higher MACE.
ACC 2021 Risk of new-onset AF was reduced by 29% in patients randomized to finerenone compared to placebo in a population of patients with T2DM and CKD.
ACC 2021 In patients who had used DAPT for 6-18 months after PCI with DES, clopidogrel monotherapy as chronic maintenance therapy for 2 years reduced ischemic and bleeding outcomes compared to aspirin monotherapy.
ACC 2021 Prof. Ridker talks about anti-inflammatory therapies to prevent CVD: What is the right drug and what is the right target population?
ACC 2021 The phase 2 RESCUE trial showed that the IL-6 inhibitor ziltivekimab largely reduced hsCRP and other biomarkers of inflammation and thrombosis in patients with CKD and ≥2 mg/L hsCRP.
Experts in dialogue In a video on management of statin-intolerant patients, the discussants state that we are in a good position in 2021 with new options of lipid-lowering therapies for these patients.
Experts in dialogue Two lipid experts discuss what the possible barriers are for implementing guidelines and not reaching goals with regard to LDL-c and how to overcome these barriers.